Skip to content
2000
Volume 21, Issue 5
  • ISSN: 1573-398X
  • E-ISSN: 1875-6387

Abstract

Background

The aim of this study is to systematically review and analyze the incidence and outcomes of COVID-19 in patients with pulmonary hypertension (PH).

Methods

We searched PubMed, SCOPUS, Web of Science, and Embase for relevant publications up to March 27th, 2024. Articles were screened for studies on the incidence or outcomes of COVID-19 in PH patients. Screening, data extraction, and risk of bias assessment were performed independently in duplicate. When possible, relevant results were pooled using the random effects model.

Results

Of the 5,981 articles, a total of 30 were included in the systematic review and 29 in the meta-analysis. The incidence rate of COVID-19 in PH patients was 25 (15-41) per 100,000 person-day. The hospitalization rate was 47% (26.4-68.7), and the mean duration of hospitalization was 10.033 (9.644-10.422) ± 0.198 days. The rate of admission to the intensive care unit was 35.8% (23.9-49.9) and mechanical ventilation was required in 17.4% (11.6-25.3) of hospitalized patients. The in-hospital mortality rate was 23.1% (21.6-24.6). Further analysis of studies comparing COVID-19 patients with and without PH showed a higher mortality rate in COVID-19 patients with PH (OR = 1.722 CI 95% (1.393-2.128), < 0.0001, I2 = 99%). Meta-regression showed no significant association between sex and the incidence of COVID-19 infection in PH patients.

Conclusion

Pre-existing PH may not be associated with a higher incidence of COVID-19 but may be associated with worsening outcomes of COVID-19 infection.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crmr/10.2174/011573398X359152250422111047
2025-04-28
2025-12-09

  • From This Site

    /content/journals/crmr/10.2174/011573398X359152250422111047
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MaronB.A. BrittainE.L. HessE. WaldoS.W. BarónA.E. HuangS. GoldsteinR.H. AssadT. WertheimB.M. AlbaG.A. LeopoldJ.A. OlschewskiH. GalièN. SimonneauG. KovacsG. TedfordR.J. HumbertM. ChoudharyG. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: A retrospective cohort study.Lancet Respir. Med.20208987388410.1016/S2213‑2600(20)30317‑932730752
     [Google Scholar]
  2. OliveiraA.P.S. CampoyA.T. OliveiraR.K.F. Ota-ArakakiJ.S. FerreiraE.V.M. Pulmonary hypertension outcomes during the COVID-19 pandemic in Brazil.J. Bras. Pneumol.2023495e20230020
     [Google Scholar]
  3. WuX. LiJ. MaJ. LiuQ. WangL. ZhuY. CuiY. WangA. WenC. QiuL. YangY. LuD. XuX. ZhuX. ChengC. WangD. JingZ. Vaccination against coronavirus disease 2019 in patients with pulmonary hypertension: A national prospective cohort study.Chin. Med. J.202413766997537439342
     [Google Scholar]
  4. SalabeiJ.K. AsnakeZ.T. IsmailZ.H. CharlesK. StangerG.T. AbdullahiA.H. AbrahamA.T. OkonobohP. COVID-19 and the cardiovascular system: An update.Am. J. Med. Sci.2022364213914710.1016/j.amjms.2022.01.02235151635
     [Google Scholar]
  5. CalverJ.F. FabbriL. MayJ. JenkinsR.G. COVID-19 in patients with chronic lung disease.Clin. Chest Med.202344238539310.1016/j.ccm.2022.11.01337085227
     [Google Scholar]
  6. RahmatiM. ShamsiM.M. KhoramipourK. MalakoutiniaF. WooW. ParkS. YonD.K. LeeS.W. ShinJ.I. SmithL. Baseline physical activity is associated with reduced mortality and disease outcomes in COVID-19: A systematic review and meta-analysis.Rev. Med. Virol.2022325e234910.1002/rmv.234935416354
     [Google Scholar]
  7. ShinJ.I. KimS.E. LeeM.H. KimM.S. LeeS.W. ParkS. ShinY.H. YangJ.W. SongJ.M. MoonS.Y. KimS.Y. ParkY. SuhD.I. YangJ.M. ChoS.H. JinH.Y. HongS.H. WonH.H. KronbichlerA. KoyanagiA. JacobL. HwangJ. TizaouiK. LeeK.H. KimJ.H. YonD.K. SmithL. COVID-19 susceptibility and clinical outcomes in autoimmune inflammatory rheumatic diseases (AIRDs): A systematic review and meta-analysis.Eur. Rev. Med. Pharmacol. Sci.202226103760377035647859
     [Google Scholar]
  8. ParkS.H. HongS.H. KimK. LeeS.W. YonD.K. JungS.J. AbdeenZ. GhaydaR.A. AhmedM.L.C.B. SerouriA.A. Al-HerzW. Al-ShamsiH.O. AliS. AliK. BaatarkhuuO. NielsenH.B. Bernini-CarriE. BondarenkoA. CassellA. ChamA. ChuaM.L.K. DadabhaiS. DarreT. DavtyanH. DragiotiE. EastB. EdwardsR.J. FerioliM. GeorgievT. GhandourL.A. HarapanH. HsuehP.R. MallahS.I. IkramA. InoueS. JacobL. JankovićS.M. JayarajahU. JesenakM. KakodkarP. KapataN. KebedeY. KhaderY. KifleM. KohD. MalešV.K. KotfisK. KoyanagiA. KretchyJ.P. LakohS. LeeJ. LeeJ.Y. MendonçaM.L.L. LingL. Llibre-GuerraJ. MachidaM. MakurumidzeR. MemishZ.A. MendozaI. MoiseevS. NadasdyT. NahshonC. Ñamendys-SilvaS.A. YongsiB.N. NicolasoraA.D. NugmanovaZ. OhH. OksanenA. OwopetuO. OzgulerZ.O. ParperisK. PerezG.E. PongpirulK. RademakerM. RadojevicN. RocaA. Rodriguez-MoralesA.J. RoshiE. SaeedK.M.I. SahR. SakakushevB. SallamD.E. SathianB. SchoberP. AliP.S.S. SimonovićZ. SinghalT. SkhvitaridzeN. SolmiM. SubbaramK. TizaouiK. TlhakaneloJ.T. ToralesJ. Torres-RomanJ.S. TsartsalisD. TsolmonJ. VieiraD.N. RosaS.G.V. WanghiG. WollinaU. XuR.H. YangL. ZiaK. ZildzicM. Il ShinJ. SmithL. Nonpharmaceutical interventions reduce the incidence and mortality of COVID-19: A study based on the survey from the International COVID-19 research network (ICRN).J. Med. Virol.2023952e2835410.1002/jmv.2835436447130
     [Google Scholar]
  9. BelgeC. QuarckR. GodinasL. MontaniD. Escribano SubiasP. VachiéryJ.L. NashatH. Pepke-ZabaJ. HumbertM. DelcroixM. COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A reference centre survey.ERJ Open Res.20206400520-202010.1183/23120541.00520‑202033263061
     [Google Scholar]
  10. LeeJ.D. BurgerC.D. DelossantosG.B. GrinnanD. RalphD.D. RaynerS.G. RyanJ.J. SafdarZ. VentetuoloC.E. ZamanianR.T. LearyP.J. A survey-based estimate of COVID-19 incidence and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension and impact on the process of care.Ann. Am. Thorac. Soc.202017121576158210.1513/AnnalsATS.202005‑521OC32726561
     [Google Scholar]
  11. Smukowska-GoryniaA. IwańczykS. RzymskiP. WoźniakP. GościniakW. Mularek-KubzdelaT. Patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension during the COVID-19 pandemic (2020-2022): Clinical outcomes, prognostic factors, and response to vaccination. Pol. Arch. Intern. Med.2024134316706
     [Google Scholar]
  12. KovacsG. BartolomeS. DentonC.P. GatzoulisM.A. GuS. KhannaD. BadeschD. MontaniD. Definition, classification and diagnosis of pulmonary hypertension.Eur. Respir. J.2024644240132410.1183/13993003.01324‑202439209475
     [Google Scholar]
  13. MoherD. ShamseerL. ClarkeM. GhersiD. LiberatiA. PetticrewM. ShekelleP. StewartL.A. PRISMA-P Group Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.Syst. Rev.201541110.1186/2046‑4053‑4‑125554246
     [Google Scholar]
  14. MoolaS. MunnZ. TufanaruC. AromatarisE. SearsK. SfetcuR. CurrieM. QureshiR. MattisP. LisyK. Systematic reviews of etiology and risk.JBI Manual for Evidence SynthesisAdelaide. JBI; 2017. p. 217-69.
     [Google Scholar]
  15. WanX. WangW. LiuJ. TongT. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range.BMC Med. Res. Methodol.201414113510.1186/1471‑2288‑14‑13525524443
     [Google Scholar]
  16. SterneJ. EggerM. Regression methods to detect publication and other bias in meta-analysisPublication bias in meta-analysis: Prevention, assessment and adjustmentsWiley2005p. 99-110.
     [Google Scholar]
  17. SchererR.W. SaldanhaI.J. How should systematic reviewers handle conference abstracts? A view from the trenches.Syst. Rev.20198126410.1186/s13643‑019‑1188‑031699124
     [Google Scholar]
  18. AslamA. COVID-19 outcomes in patients with pulmonary hypertension: A retrospective cohort analysis.Chest20211604A250910.1016/j.chest.2021.08.018
     [Google Scholar]
  19. SeratiA. KeshmiriM.S. ShafaghiS. MohammadM.M. KashaniB.S. NaghashzadehF. MohamadifarA. ShafaghiM. NooraliS. HajimoradiM. AstaniB. AghdasiS. RiahiM. AlaviS. MalekR. MovahedM.R. The outcome of patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension during the COVID-19 pandemic.Crit. Pathw. Cardiol.2023222606410.1097/HPC.000000000000031737220659
     [Google Scholar]
  20. EvbayekhaE. NriaguB. IdowuA. OkorareO. Adabale OkohA. Recent trends in pulmonary hypertension hospitalizations and outcomes in the subgroup patients hospitalized with SARS-CoV-2 (COVID) virus infection. A population-based retrospective study.J. Card. Fail.202430123523510.1016/j.cardfail.2023.10.281
     [Google Scholar]
  21. HornE.M. ChakinalaM. OudizR. JoseloffE. RosenzweigE.B. Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19?Pulm. Circ.20201021210.1177/204589402092279932426113
     [Google Scholar]
  22. KodaliM. AtluriR. Abstract 19002: Impact of pulmonary hypertension on COVID-19 pneumonia hospitalizations: Analysis of the national inpatient sample 2020.Circulation2023148(Suppl. 1)14810.1161/circ.148.suppl_1.19002
     [Google Scholar]
  23. PrasannaL.S. MohammedA. GandhiZ.J. MeruguB. LapsiwalaB. Srivalli KonakanchiS. ChilukaS. Amrutha Sai YallaN. VijayakumarS. PrabhuS. BreretonB.J. UsmanS. DesaiR. Burden and impact of secondary (NON-GROUP 1) pulmonary hypertension on outcomes OF COVID-19-related hospitalizations in heart failure patients with preserved ejection fraction.Chest20231644A5996A599710.1016/j.chest.2023.07.3865
     [Google Scholar]
  24. MajeedH. CannonH.R. RajK. NasrullahA. MajeedS. GanguK. FarooqA. SheikhA.B. COVID-19 patients with pulmonary hypertension hospitalized in the united states during the early pandemic: Analysis of in-hospital mortality, clinical outcomes, and racial disparities.Curr. Probl. Cardiol.2023481110193310.1016/j.cpcardiol.2023.10193337422043
     [Google Scholar]
  25. Morales-DemoriR. MalloryG.B. ChartanC. ColemanR. RuizF. VillafrancoN. WhalenE. VargheseN. Outcomes of COVID-19 infection in pediatric pulmonary hypertension: A single-center experience.Pediatr. Pulmonol.202156123960396510.1002/ppul.2565034460150
     [Google Scholar]
  26. SulicaR. CefaliF. MotschwillerC. FentonR. BarrosoA. StermanD. COVID-19 in pulmonary artery hypertension (PAH) patients: Observations from a large PAH center in New york city. Diagnostics2021111128
     [Google Scholar]
  27. TirmiziZ. SelvamA.S. PatelK. LahoriY. KonchwallaA. ShahH. Alishan Ahmed TirmiziS. PatelU. In-hospital mortality and outcomes in pulmonary hypertension patients admitted with COVID-19.Chest20231644A84010.1016/j.chest.2023.07.625
     [Google Scholar]
  28. MamzerA. WaligoraM. KopecG. Ptaszynska-KopczynskaK. KurzynaM. DarochaS. FlorczykM. MroczekE. Mularek-KubzdelaT. Smukowska-GoryniaA. WrotynskiM. ChrzanowskiL. Dzikowska-DiduchO. Perzanowska-BrzeszkiewiczK. PruszczykP. SkoczylasI. LewickaE. BlaszczakP. KarasekD. Kusmierczyk-DroszczB. Mizia-StecK. KaminskiK. JachecW. Peregud-PogorzelskaM. DoboszynskaA. GasiorZ. TomaszewskiM. PawlakA. ZablockaW. RyczekR. Widejko-PietkiewiczK. KasprzakJ.D. Impact of the COVID-19 pandemic on pulmonary hypertension patients: Insights from the BNP-PL national database.Int. J. Environ. Res. Public Health20221914842310.3390/ijerph1914842335886278
     [Google Scholar]
  29. Wieteska-MiłekM. Kuśmierczyk-DroszczB. RyczekR. SzmitS. FlorczykM. MańczakR. Betkier-LipińskaK. HoffmanP. KrzesińskiP. TorbickiA. Outcomes of COVID-19 in patients vaccinated and unvaccinated against SARS-CoV-2 and suffering from pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Pol. Arch. Intern. Med.2023133516406
     [Google Scholar]
  30. HinojosaW. Cristo-RoperoM.J. Cruz-UtrillaA. Segura de la CalT. López-MedranoF. Salguero-BodesR. Pérez-OlivaresC. NavarroB. OchoaN. Arribas YnsurriagaF. Escribano-SubiasP. The impact of COVID-19 pandemic on pulmonary hypertension: What have we learned?Pulm. Circ.2022124e1214210.1002/pul2.1214236238968
     [Google Scholar]
  31. NucheJ. Pérez-OlivaresC. de la CalT.S. López-GuarchC.J. YnsaurriagaF.A. SubíasP.E. Clinical course of COVID-19 in pulmonary arterial hypertension patients.Rev. Esp. Cardiol.202073977577810.1016/j.recesp.2020.05.028
     [Google Scholar]
  32. BadagliaccaR. PapaS. D’AltoM. GhioS. AgostoniP. AmeriP. ArgientoP. BrunettiN.D. CasamassimaV. CasuG. CedroneN. ConfalonieriM. CordaM. CorrealeM. D’AgostinoC. De MicheleL. FamosoG. GalganoG. GrecoA. LombardiC.M. ManziG. MadonnaR. MercurioV. MulèM. PacioccoG. RomanielloA. RomeoE. ScelsiL. SerraW. StolfoD. TomaM. VatranoM. VituloP. VizzaC.D. The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: Is risk of disease progression around the corner?Eur. Respir. J.2022604210227610.1183/13993003.02276‑202135301247
     [Google Scholar]
  33. LouisD. SheikhW. SaadM. HasP. kennedy AronowH.D. ChoudharyG. Abstract 10384: Impact of preexisting pulmonary hypertension on outcomes in patients hospitalized with COVID-19.Circulation2022146(Suppl. 1)14610.1161/circ.146.suppl_1.10384
     [Google Scholar]
  34. MontaniD. CertainM.C. WeatheraldJ. JaïsX. BulifonS. Noel-SavinaE. NievesA. RénardS. TracletJ. BouvaistH. RiouM. de GrooteP. MoceriP. BertolettiL. FavroltN. GuillaumotA. JutantE.M. BeurnierA. BouclyA. EbsteinN. JevnikarM. PichonJ. KeddacheS. PredaM. RocheA. SolinasS. SeferianA. Reynaud-GaubertM. CottinV. SavaleL. HumbertM. SitbonO. KaisA. EliseA.M. CélineC. AriC. surnameClaireD. FrédéricG. AnneG. SébastienH. DelphineH.L. JocelynI. BouchraL. PascalM. Jean-ClaudeM. PatriceP. GrégoireP. RogerR. ServettazA. COVID-19 in patients with pulmonary hypertension: A National prospective cohort study.Am. J. Respir. Crit. Care Med.2022206557358310.1164/rccm.202112‑2761OC35549842
     [Google Scholar]
  35. FarmakisI.T. KaryofyllisP. FrantzeskakiF. DemeroutiE. AnthiA. ArvanitakiA. PitsiouG. NakaK.K. BechlioulisA. ThomaidiA. AvgeropoulouA. BriliS. MitrouskaI. ManginasA. OrfanosS.E. TsangarisI. GiannakoulasG. Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the hellenic pulmonary hypertension registry (HOPE).Hellenic J. Cardiol.202264939610.1016/j.hjc.2021.10.00234843997
     [Google Scholar]
  36. SolimanY.M.A. ElkorashyR.I.M. AzizA.A. AbdelnabyA. MagdyS. Impact and predictors of outcome of COVID-19 in pulmonary hypertension patients.Egypt. J. Bronchol.20221615610.1186/s43168‑022‑00158‑2
     [Google Scholar]
  37. BevacquaR.J. PerroneS.V. The impact of COVID-19 on pulmonary arterial hypertension.Insuf. Card.20211637989
     [Google Scholar]
  38. GodinasL. IyerK. MeszarosG. QuarckR. Escribano-SubiasP. Vonk NoordegraafA. JansaP. D’AltoM. LuknarM. Milutinov IlicS. BelgeC. SitbonO. ReisA. RosenkranzS. Pepke-ZabaJ. HumbertM. DelcroixM. PH CARE COVID survey: An international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic.Orphanet J. Rare Dis.202116119610.1186/s13023‑021‑01752‑133933110
     [Google Scholar]
  39. SchmidtK.H. MilgerK. PauschC. HuscherD. PittrowD. GrünigE. StaehlerG. GallH. DistlerO. SkowaschD. HalankM. WilkensH. HeldM. KloseH. HoeperM.M. Trends in COVID-19-associated mortality in patients with pulmonary hypertension: A COMPERA analysis.Eur. Respir. J.2023614220244010.1183/13993003.02440‑202237105586
     [Google Scholar]
  40. DeSalvoJ. FrancoV. BenzaR.L. DanielsC. KittelD. AlexanderA. HomsyE. LastingerL. RajpalS. Abstract 11614: Investigating outcomes in patients with pulmonary hypertension diagnosed with COVID-19 in a tertiary pulmonary hypertension referral center.Circulation2021144(Suppl. 1)14410.1161/circ.144.suppl_1.11614
     [Google Scholar]
  41. feldman wilson KantorovichA. DeRuiterA. SchreurK. ClassiP. NelsenA. Abstract 15745: Health outcomes in pulmonary arterial hypertension patients with COVID-19: A real-world analysis.Circulation2020142Suppl. 314210.1161/circ.142.suppl_3.15745
     [Google Scholar]
  42. SirenkoY. ZhyviloI. RadchenkoG. COVID-19 morbidity and outcomes among the patients observed in the pulmonary hypertension reference center.Eur. Heart J.202142(Suppl. 1)ehab724.190110.1093/eurheartj/ehab724.1901
     [Google Scholar]
  43. AkbariA. FathabadiA. RazmiM. ZarifianA. AmiriM. GhodsiA. Vafadar MoradiE. Characteristics, risk factors, and outcomes associated with readmission in COVID-19 patients: A systematic review and meta-analysis.Am. J. Emerg. Med.20225216617310.1016/j.ajem.2021.12.01234923196
     [Google Scholar]
  44. MarroJ. BallejoC. AguirreM.F. MartínM.E.S. MirandaL.L. PoncetV. SilvaA. Prospective cohort study in the early stage of the COVID-19 pandemic, General Pueyrredón, Argentina (INECOVID): Infection dynamics and risk factors.Rev. Bras. Epidemiol.202124e210055
     [Google Scholar]
  45. MengistB. AnimutZ. TolossaT. Incidence and predictors of mortality among COVID-19 patients admitted to treatment centers in North West Ethiopia; A retrospective cohort study, 2021.Int. J. Afr. Nurs. Sci.20221610041910.1016/j.ijans.2022.10041935530744
     [Google Scholar]
  46. BialekS. BowenV. ChowN. CurnsA. GierkeR. HallA. HughesM. PilishviliT. RitcheyM. RoguskiK. SilkB. SkoffT. SundararamanP. UsseryE. VasserM. WhithamH. WenJ. Geographic differences in COVID-19 cases, deaths, and incidence — United States, february 12–april 7, 2020.MMWR Morb. Mortal. Wkly. Rep.2020691546547110.15585/mmwr.mm6915e432298250
     [Google Scholar]
  47. HemnesA.R. RathinasabapathyA. AustinE.A. BrittainE.L. CarrierE.J. ChenX. FesselJ.P. FikeC.D. FongP. FortuneN. GersztenR.E. JohnsonJ.A. KaplowitzM. NewmanJ.H. PianaR. PughM.E. RiceT.W. RobbinsI.M. WheelerL. YuC. LoydJ.E. WestJ. A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension.Eur. Respir. J.2018516170263810.1183/13993003.02638‑201729903860
     [Google Scholar]
  48. AkbariA. HadizadehA. IslampanahM. Salavati NikE. AtkinS.L. SahebkarA. COVID-19, G protein-coupled receptor, and renin-angiotensin system autoantibodies: Systematic review and meta-analysis.Autoimmun. Rev.202322910340210.1016/j.autrev.2023.10340237490975
     [Google Scholar]
  49. DanserA.H.J. EpsteinM. BatlleD. Renin-angiotensin system blockers and the COVID-19 pandemic: At present there is no evidence to abandon renin-angiotensin system blockers.Hypertension202075613821385
     [Google Scholar]
  50. KubaK. ImaiY. RaoS. GaoH. GuoF. GuanB. HuanY. YangP. ZhangY. DengW. BaoL. ZhangB. LiuG. WangZ. ChappellM. LiuY. ZhengD. LeibbrandtA. WadaT. SlutskyA.S. LiuD. QinC. JiangC. PenningerJ.M. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury.Nat. Med.200511887587910.1038/nm126716007097
     [Google Scholar]
  51. VaughanL. VeruttipongD. ShawJ.G. LevyN. EdwardsL. WingetM. Relationship of socio-demographics, comorbidities, symptoms and healthcare access with early COVID-19 presentation and disease severity.BMC Infect. Dis.20212114010.1186/s12879‑021‑05764‑x33421991
     [Google Scholar]
  52. KimuraD. McNamaraI.F. WangJ. FowkeJ.H. WestA.N. PhilipR. Pulmonary hypertension during respiratory syncytial virus bronchiolitis: A risk factor for severity of illness.Cardiol. Young201929561561910.1017/S104795111900031331104634
     [Google Scholar]
  53. AckermannM. VerledenS.E. KuehnelM. HaverichA. WelteT. LaengerF. VanstapelA. WerleinC. StarkH. TzankovA. LiW.W. LiV.W. MentzerS.J. JonigkD. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19.N. Engl. J. Med.2020383212012810.1056/NEJMoa201543232437596
     [Google Scholar]
  54. MariniJ.J. GattinoniL. Management of COVID-19 respiratory distress.JAMA2020323222329233010.1001/jama.2020.682532329799
     [Google Scholar]
  55. LeeC.J. WooW. KimA.Y. YonD.K. LeeS.W. KoyanagiA. KimM.S. TizaouiK. DragiotiE. RaduaJ. LeeS. SmithL. Il ShinJ. Clinical manifestations of COVID-19 breakthrough infections: A systematic review and meta-analysis.J. Med. Virol.20229494234424510.1002/jmv.2787135588301
     [Google Scholar]
  56. MurthyS. GomersallC.D. FowlerR.A. Care for critically Ill patients with COVID-19.JAMA2020323151499150010.1001/jama.2020.363332159735
     [Google Scholar]
  57. KimS. LeeH. LeeJ. LeeS.W. KwonR. KimM.S. KoyanagiA. SmithL. FondG. BoyerL. RahmatiM. López SánchezG.F. DragiotiE. CorteseS. ShinJ.Y. ChoiA. SuhH.S. LeeS. SolmiM. MinC. ShinJ.I. YonD.K. Fusar-PoliP. Short- and long-term neuropsychiatric outcomes in long COVID in South Korea and Japan.Nat. Hum. Behav.2024881530154410.1038/s41562‑024‑01895‑838918517
     [Google Scholar]
/content/journals/crmr/10.2174/011573398X359152250422111047
Loading
Incidence and Outcomes of COVID-19 in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis
Curr. Respir. Med. Rev. 21, 516 (2025); https://doi.org/10.2174/011573398X359152250422111047
/content/journals/crmr/10.2174/011573398X359152250422111047
/content/journals/crmr/10.2174/011573398X359152250422111047
Loading

Data & Media loading...

Supplements

PRISMA checklist and supplementary materials are available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): COVID-19; incidence; meta-analysis; meta-regression; mortality rate; Pulmonary hypertension

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test